The Anti-Infectives Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities

Table of Contents

• Disease overview and epidemiology
• Global market analysis
• Pipeline analysis
• Competitive landscape

• Scope
  • Key drug-classes covered in this report
• Methodology

• Summary
• Introduction
• Bacterial infections
• Overview
  • Respiratory tract infections
  • Urinary tract infections
  • Skin and skin structure infections
• Pharmacological treatment
  • Penicillins
  • Cephalosporins
  • Quinolones
  • Macrolides
  • Vaccines
• Estimated incidence of bacterial infections
  • Respiratory tract infections
  • Urinary tract infections
  • Skin and skin structure infections
• Forecast epidemiology
  • Respiratory tract infections
  • Urinary tract infections
  • Skin and skin structure infections
• Viral infections
• AIDS/HIV
  • Pharmacological treatment
  • Estimated incidence of HIV
• Hepatitis
  • Pharmacological treatment for hepatitis
  • Estimated incidence of Hepatitis
  • Forecast epidemiology
• Influenza
  • Pharmacological treatment for influenza
  • Estimated incidence of Influenza
• Herpes
  • Pharmacological treatment for herpes
  • Estimated incidence of herpes
  • Forecast epidemiology
• Other viral infections
  • Human papillomavirus
  • Rotavirus
• Fungal infections
  • Pharmacological treatment for fungal infections
• Estimated incidence of fungal infections
• Forecast epidemiology

• Summary
• Introduction
• Market analysis by country
• Licensing trends
• Market analysis by drug classes
• Leading brands dynamics
• Key events in the anti-infectives market
• Modest growth from Quinolones
• Drug resistant infections confer long term growth opportunity
• Novel HIV/AIDS drugs present substantial market opportunity
• Hepatitis C therapies fuel strong growth through 2013
• Novel vaccines drive future sales growth
• Global concerns on potential human avian flu epidemic

• Anti-bacterials
• Market analysis by drug class
• Leading brands of anti-bacterial treatments
• Cephalosporins
  • Key brand analysis
• Penicillins
  • Key brand analysis
• Fluoroquinolones
  • Key brand analysis
• Macrolides
  • Key brand analysis
• Carbapenems
  • Key brand analysis
• Tetracyclines
  • Key brand analysis
• Other antibiotics
  • Key brand analysis
• Anti-bacterials sales forecast (2008- 2013)

• Anti-virals
• Breakdown of the global anti-virals market
• Leading brands of anti-virals treatment
  • Key brand analysis
• Anti-virals sales forecasts (2008 - 2013)

• Vaccines
• Breakdown of the global vaccines market
• Leading brands of vaccines
  • Key brand analysis
• Vaccines sales forecasts 2008- 2013

• Anti-fungals
• Breakdown of the global anti-fungals market
• Leading brands of anti-fungals treatment
  • Key brand analysis
• Anti-fungals sales forecasts 2008-2013
• Total anti-infective market sales forecasts to 2013

• Summary
• Introduction

• Key trends in R&D
• Key trends in the anti-bacterial market
• Key trends in the anti-viral market
• Key trends in the vaccines market
• Key trends in the anti-fungal market
• Therapeutic area pipeline
• Leading drugs in development
• Profiles of key pipeline products
• Recently marketed drugs
  • Doribax
  • Isentress
  • Prezista
  • Selzentry
  • Eraxis
  • Gardasil
• Drugs in registration
  • Ceftobiprole
  • Cervarix
• Drugs in phase III clinical studies
  • Albuferon
  • Tygacil
  • Numax
  • Telaprevir
  • Vicriviroc
  • Menveo
  • Prevnar 13vPnC
• Pipeline forecast
• Factors affecting forecasts
• Anti-bacterials
• Anti-virals
• Anti-fungals
• Vaccines

• Summary
• Introduction
• Sales performance among the leading players
• Detailed analysis of leading anti-infective players
• GlaxoSmithKline
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
• Merck
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
• Pfizer
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
• Novartis
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
• Gilead Sciences
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
• Abbott
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
• Wyeth
  • Overview
  • Sales Focus By Drug class
  • Marketed Product Portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
• Sanofi-Aventis
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • Strategic and growth analysis
• Bristol-Myers Squibb
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic growth analysis
• Johnson & Johnson
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic growth analysis

• IMS data
• J1 Systemic antibiotics
• J2 Systemic agents for fungal infections
• J5 Antivirals for systemic use
• J7 Vaccines
• Index

List of Figures

• Figure 3.1: Global anti-infectives market share by geography (%), global, 2007
• Figure 3.2: Sales revenuesof anti-infectives by licensing status ($m), global, 2006- 2007
• Figure 4.3: Key trends in the anti-infectives R&D pipelines, 2007-2013
• Figure 4.4: Anti-infectives pipeline by indication and stage of development, March 2008
• Figure 4.5: Leading drugs in development, March 2008
• Figure 4.6: Anti-bacterial pipeline forecast, 2007- 2013
• Figure 4.7: Anti-viral pipeline forecast, 2007- 2013
• Figure 4.8: Anti-fungal pipeline forecast, 2007- 2013
• Figure 4.9: Vaccines pipeline forecast, 2007- 2013
• Figure 5.10: Market share of key players by sales revenues, 2007
• Figure 5.11: Forecast market share of leading anti-infectives players by sales revenues, 2013
• Figure 5.12: Market share and ranking of leading players in the global anti-infectives market, 2007 - 2013
• Figure 5.13: GSK' s anti-infectives product portfolio by drug class, 2007
• Figure 5.14: Merck' s anti-infectives product portfolio by drug class, 2007
• Figure 5.15: Pfizer' s anti-infectives product portfolio by drug class, 2007
• Figure 5.16: Novartis anti-infectives product portfolio by drug class, 2007
• Figure 5.17: Gilead Science' s anti-infectives product portfolio by drug class, 2007
• Figure 5.18: Abbott' s anti-infectives product portfolio by drug class, 2007
• Figure 5.19: Wyeth' s anti-infectives product portfolio by drug class, 2007
• Figure 5.20: Sanofi-Aventis' anti-infectives product portfolio by drug class, 2007
• Figure 5.21: Bristol - Myers Squibb' s anti-infectives product portfolio by drug class, 2007
• Figure 5.22: J&J' s anti-infectives product portfolio by drug class, 2007

List of Tables

• Table 2.1: Estimated incidence of infective diseases, EU5, US and Japan, 2005
• Table 2.2: Estimated incidence of community acquired pneumonia infections EU5, US and Japan, 2007
• Table 2.3: Estimated incidence of upper RTIs caused by streptococcus infection, EU5, US and Japan, 2007
• Table 2.4: Estimated incidence of community acquired urinary tract infections, EU5, US and Japan, 2007
• Table 2.5: Estimated incidence of bacterial skin and skin structure infections, EU5, US and Japan, 2007
• Table 2.6: Forecast epidemiology of CAP, EU5, US and Japan, 2007- 2013
• Table 2.7: Forecast epidemiology of uRTIs caused by streptococcus infection, Eu5, US and Japan, 2007- 2013
• Table 2.8: Forecast epidemiology of urinary tract infections, EU5, US and Japan, 2007- 2013
• Table 2.9: Forecast epidemiology of skin and skin structure infections, EU5, US and Japan, 2007- 2013
• Table 2.10: HIV/AIDS incidence and prevalence ($m), 2005
• Table 2.11: Estimated incidence of community acquired HBV and HCV infection (' 000s), EU5, US and Japan, 2007
• Table 2.12: Forecast epidemiology of HBV, EU5, US and Japan, 2007- 13
• Table 2.13: Forecast epidemiology of HCV, EU5, US and Japan, 2007- 13
• Table 2.14: Estimated seroprevalence of HSV - 1 and HSV - 2 infections (' 000s), Eu5, US and japan, 2007
• Table 2.15: Forecast seroprevalence of HSV 1, EU5, US and Japan, 2007- 13
• Table 2.16: Forecast seroprevalence of HSV 2 across the seven major markets, 2007- 2013
• Table 2.17: Estimated incidence of systemic fungal infections (' 000s) in EU5, US and Japan, 2007
• Table 2.18: Forecast epidemiology of systemic fungal infections, EU5, US and Japan, 2007- 2013
• Table 3.19: Breakdown of the global anti-infectives market by drug class ($m), 2006- 2007
• Table 3.20: Leading brands in the global anti-infectives market ($m), 2006- 2007
• Table 3.21: Breakdown of the global anti-bacterial market by drug class ($m), 2006- 2007
• Table 3.22: Leading anti-bacterials in the global anti-infectives market ($m), 2006- 2007
• Table 3.23: Leading cephalosporins in the global anti-infectives market ($m), 2006- 2007
• Table 3.24: Leading penicillins in the global anti-infectives market ($m), 2006- 2007
• Table 3.25: Leading fluoroquinolones in the global anti-infectives market ($m), 2006- 2007
• Table 3.26: Leading macrolides in the global anti-infectives market ($m), 2006- 2007
• Table 3.27: Leading carbapenems in the global anti-infectives market ($m), 2006- 2007
• Table 3.28: Leading tetracyclines in the global anti-infectives market ($m), 2006- 2007
• Table 3.29: Leading other anti-bacterials in the global anti-infectives market ($m), 2006- 2007
• Table 3.30: Anti-bacterials sales forecast ($m), global, 2008- 2013
• Table 3.31: Anti-bacterials sales forecast ($m), global, 2008- 2013 (continued)
• Table 3.32: Anti-bacterials sales forecast ($m), global, 2008- 2013
• Table 3.33: Breakdown of the global anti-virals market by drug class ($m), 2006- 2007
• Table 3.34: Leading antivirals in the global anti-infectives market ($m), 2006- 2007
• Table 3.35: Anti-virals sales forecast ($m), global, 2008-2013
• Table 3.36: Breakdown of the global vaccines market by class ($m), 2006- 2007
• Table 3.37: Leading vaccines in the global anti-infectives market ($m), 2006- 2007
• Table 3.38: Global vaccines sales forecast, 2008- 2013 ($m)
• Table 3.39: Global anti-fungal market, ($m), 2006- 2007
• Table 3.40: Leading anti-fungal brands in the global anti-infectives market ($m), 2006- 2007
• Table 3.41: Global anti-fungals sales forecast ($m), 2008- 2013
• Table 3.42: Global anti-infectives sales forecast ($m), 2008- 2013
• Table 4.43: Key drug profile, Doripenem
• Table 4.44: An overview onIsentress
• Table 4.45: An overview onPrezista
• Table 4.46: An overview on Selzentry
• Table 4.47: An overview on Eraxis
• Table 4.48: An overview on Gardasil
• Table 4.49: FDA approvals and NDA filings of Gardasil
• Table 4.50: An overview on Ceftobiprole
• Table 4.51: An overview on Cervarix
• Table 4.52: An overview on Albuferon
• Table 4.53: An overview on Tygacil
• Table 4.54: An overview on Motavizumab
• Table 4.55: An overview on Telaprevir
• Table 4.56: An overview on Vicriviroc
• Table 4.57: An overview on Menveo
• Table 4.58: An overview on Prevna13vPnC
• Table 5.59: Sales performance of the leading players in the global anti-infectives market ($m),2006- 2007
• Table 5.60: GSK' s leading anti-infectives product sales ($m), 2006- 2007
• Table 5.61: GSK' s anti-infectives product pipeline, 2006- 2007
• Table 5.62: Merck' s leading anti-infectives product sales ($m), 2006- 2007
• Table 5.63: Merck' s anti-infectives product pipeline, 2006- 2007
• Table 5.64: Pfizer' s anti-infectives product portfolio, 2006- 2007 ($m)
• Table 5.65: Pfizer' s anti-infectives product pipeline, 2006- 2007
• Table 5.66: Novartis' anti-infectives product portfolio, 2006- 2007 ($m)
• Table 5.67: Novartis' anti-infectives product pipeline, 2006- 2007
• Table 5.68: Gilead Sciences' leading anti-infectives product sales, 2006- 2007 ($m)
• Table 5.69: Gilead Sciences' anti-infectives product pipeline, 2006- 2007
• Table 5.70: Abbott' s leading anti-infectives product sales, 2006- 2007 ($m)
• Table 5.71: Abbott' s anti-infectives product pipeline, 2006- 2007
• Table 5.72: Wyeth' s leading anti-infectives product sales, 2006- 2007
• Table 5.73: Wyeth' s anti-infectives product pipeline, 2006- 2007
• Table 5.74: Sanofi-Aventis' leading anti-infectives product sales, 2006- 2007 ($m)
• Table 5.75: Sanofi-Aventis' anti-infectives product pipeline, 2006- 2007
• Table 5.76: Bristol - Myers Squibb' s leading anti-infectives product sales, 2006- 2007 ($m)
• Table 5.77: Bristol - Myers Squibb' s anti-infectives product pipeline, 2006- 2007
• Table 5.78: J&J' s leading anti-infectives product sales, 2006- 2007 ($m)
• Table 5.79: J&J' s anti-infectives product pipeline, 2006- 2007